Patents by Inventor Karl Schonafinger

Karl Schonafinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8541410
    Abstract: The present invention relates to compounds of the formula I wherein A1, A2, R1, R2, R3, X and n are as defined in the claims, which are valuable pharmaceutically active compounds for the therapy and prophylaxis of diseases, for example of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis. The compounds of the formula I are capable of modulating the body's production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of the formula I.
    Type: Grant
    Filed: January 6, 2012
    Date of Patent: September 24, 2013
    Assignee: Sanofi-aventis Deutschland GmbH
    Inventors: Ursula Schindler, Karl Schönafinger, Hartmut Strobel
  • Publication number: 20120108573
    Abstract: The present invention relates to compounds of the formula I wherein A1, A2, R1, R3, X and n are as defined in the claims, which are valuable pharmaceutically active compounds for the therapy and prophylaxis of diseases, for example of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis. The compounds of the formula fare capable of modulating the body's production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of the formula I.
    Type: Application
    Filed: January 6, 2012
    Publication date: May 3, 2012
    Inventors: Ursula SCHINDLER, Karl SCHÖNAFINGER, Hartmut STROBEL
  • Patent number: 8163751
    Abstract: The present invention relates to acylated indanyl amines according to the general formula (I) wherein R1-R4 have the meanings given in the description, A is CH2, CHOH or CH—(C1-C3-alkyl), B is CH2 or CH—(C1-C3-alkyl), and R5 is an aryl or heteroaryl group, possibly substituted by the substituents listed in the description.
    Type: Grant
    Filed: March 29, 2010
    Date of Patent: April 24, 2012
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Hartmut Strobel, Paulus Wohlfart, Alena Safarova, Armin Walser, Teri Suzuki, Karl Schönafinger, Ramalinga M. Dharanipragada
  • Patent number: 8106213
    Abstract: The present invention relates to compounds of the formula I wherein A1, A2, R1, R2, R3, X and n are as defined in the claims, which are valuable pharmaceutically active compounds for the therapy and prophylaxis of diseases, for example of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis. The compounds of the formula I are capable of modulating the body's production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of the formula I.
    Type: Grant
    Filed: December 18, 2007
    Date of Patent: January 31, 2012
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Ursula Schindler, Karl Schönafinger, Hartmut Strobel
  • Publication number: 20100183712
    Abstract: The present invention relates to acylated indanyl amines according to the general formula (I) wherein R1-R4 have the meanings given in the description, A is CH2, CHOH or CH—(C1-C3-alkyl), B is CH2 or CH—(C1-C3-alkyl), and R5 is an aryl or heteroaryl group, possibly substituted by the substituents listed in the description.
    Type: Application
    Filed: March 29, 2010
    Publication date: July 22, 2010
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Hartmut STROBEL, Paulus WOHLFART, Alena SAFAROVA, Armin WALSER, Teri SUZUKI, Karl SCHÖNAFINGER, Ramalinga M. DHARANIPRAGADA
  • Patent number: 7462613
    Abstract: The present invention relates to novel pyridazinone derivatives of the general formula (I) wherein A is A1 or A2; R is unsubstituted or at least monosubstituted C1-C10-alkyl, aryl, aryl-(C1-C10-alkyl)-, heteroaryl, heteroaryl-(C1-C10-alkyl)-, heterocyclyl, heterocyclyl-(C1-C10-alkyl)-, C3-C10-cycloalkyl, polycycloalkyl, C2-C10-alkenyl or C2-C10-alkinyl and Ar is unsubstituted or at least monosubstituted aryl or heteroaryl.
    Type: Grant
    Filed: November 19, 2003
    Date of Patent: December 9, 2008
    Assignee: SANOFI-AVENTIS Deutschland GmbH
    Inventors: Swen Hölder, Thorsten Naumann, Karl Schönafinger, David William Will, Hans Matter, Günther Müller, Dominique Le Suisse, Bernard Baudoin, Thomas Rooney, Franck Halley, Gilles Tiraboschi, Cécile Combeau, Ingrid Sassoon, Anke Steinmetz
  • Publication number: 20080096936
    Abstract: The present invention relates to compounds of the formula I wherein A1, A2, R1, R2, R3, X and n are as defined in the claims, which are valuable pharmaceutically active compounds for the therapy and prophylaxis of diseases, for example of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis. The compounds of the formula I are capable of modulating the body's production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of the formula I.
    Type: Application
    Filed: December 18, 2007
    Publication date: April 24, 2008
    Inventors: Ursula Schindler, Karl Schonafinger, Hartmut Strobel
  • Patent number: 7326789
    Abstract: The present invention relates to compounds of the formula I wherein A1, A2, R1, R2, R3, X and n are as defined in the claims, which are valuable pharmaceutically active compounds for the therapy and prophylaxis of diseases, for example of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis. The compounds of the formula I are capable of modulating the body's production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of the formula I.
    Type: Grant
    Filed: April 2, 2004
    Date of Patent: February 5, 2008
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Ursula Schindler, Karl Schönafinger, Hartmut Strobel
  • Patent number: 7309701
    Abstract: The present invention relates to novel pyridazinone derivatives of the general formula (I) wherein A is A1 or A2; R is unsubstituted or at least monosubstituted C1-C10-alkyl, aryl, aryl-(C1-C10-alkyl)-, heteroaryl, heteroaryl-(C1-C10-alkyl)-, heterocyclyl, heterocyclyl-(C1-C10-alkyl)-, C3-C10-cycloalkyl, polycycloalkyl, C2-C10-alkenyl or C2-C10-alkinyl and Ar is unsubstituted or at least monosubstituted aryl or heteroaryl.
    Type: Grant
    Filed: November 19, 2003
    Date of Patent: December 18, 2007
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Swen Hölder, Thorsten Naumann, Karl Schönafinger, David William Will, Hans Matter, Günther Müller, Dominique Le Suisse, Bernard Baudoin, Thomas Rooney, Franck Halley, Gilles Tiraboschi
  • Patent number: 7300950
    Abstract: The present invention relates to pyrazole derivatives of the formula I, their preparation and their use in pharmaceuticals: in which X, R1, R1a, R2, R3, R4 and n are as defined in the claims, which are useful pharmaceutically active compounds for the therapy and prophylaxis of illnesses, for example of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis. The compounds of the formula I are capable of modulating the body's production of cyclic guanosine monophosphate “cGMP” and are generally suitable for the therapy and prophylaxis of illnesses which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the formula I, to their use for the therapy and prophylaxis of the abovementioned illnesses and for preparing pharmaceuticals for this purpose, and also to pharmaceutical preparations which comprise the compounds of the formula I.
    Type: Grant
    Filed: April 13, 2005
    Date of Patent: November 27, 2007
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Ursula Schindler, Karl Schönafinger, Hartmut Strobel
  • Publication number: 20070082897
    Abstract: The present invention relates to acylated indanyl amines according to the general formula (I) wherein R1—R4 have the meanings given in the description, A is CH2, CHOH or CH—(C1-C3-alkyl), B is CH2 or CH—(C1-C3-alkyl), and R5 is an aryl or heteroaryl group, possibly substituted by the substituents listed in the description.
    Type: Application
    Filed: October 11, 2006
    Publication date: April 12, 2007
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Hartmut STROBEL, Paulus WOHLFART, Alena SAFAROVA, Armin WALSER, Teri SUZUKI, Karl SCHONAFINGER, Ramalinga DHARANIPRAGADA
  • Patent number: 7179839
    Abstract: The present invention relates to acylated indanyl amines according to the general formula (I) wherein R1–R4 have the meanings given in the description, A is CH2, CHOH or CH—(C1–C3-alkyl), B is CH2 or CH—(C1–C3-alkyl), and R5 is an aryl or heteroaryl group, possibly substituted by the substituents listed in the description.
    Type: Grant
    Filed: February 13, 2002
    Date of Patent: February 20, 2007
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Hartmut Strobel, Paulus Wohlfart, Alena Safarova, Armin Walser, Teri Suzuki, Karl Schönafinger
  • Patent number: 7045526
    Abstract: The present invention relates to compounds of formula I: wherein R1, R2, and R3 have the meanings indicated in the specification, which are valuable pharmaceutical active compounds for the therapy and prophylaxis of diseases such as cardiovascular disorders such as high blood pressure, angina pectoris, cardiac insufficiency, thromboses, or atherosclerosis. Compounds of formula I have the ability to modulate the endogenous production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of disease states which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for the preparation of compounds of formula I, methods of therapy and prophylaxis of the designated disease states and for the production of pharmaceuticals therefor, and pharmaceutical compositions which comprise at least one compound of formula I.
    Type: Grant
    Filed: October 1, 2003
    Date of Patent: May 16, 2006
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Ursula Schindler, Karl Schönafinger, Hartmut Strobel
  • Publication number: 20050176799
    Abstract: The present invention relates to pyrazole derivatives of the formula I, their preparation and their use in pharmaceuticals: in which X, R1, R1a, R2, R3, R4 and n are as defined in the claims, which are useful pharmaceutically active compounds for the therapy and prophylaxis of illnesses, for example of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis. The compounds of the formula I are capable of modulating the body's production of cyclic guanosine monophosphate “cGMP” and are generally suitable for the therapy and prophylaxis of illnesses which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the formula I, to their use for the therapy and prophylaxis of the abovementioned illnesses and for preparing pharmaceuticals for this purpose, and also to pharmaceutical preparations which comprise the compounds of the formula I.
    Type: Application
    Filed: April 13, 2005
    Publication date: August 11, 2005
    Inventors: Ursula Schindler, Karl Schonafinger, Hartmut Strobel
  • Patent number: 6897232
    Abstract: The present invention relates to pyrazole derivatives of the formula I, their preparation and their use in pharmaceuticals: in which X, R1, R1a, R2, R3, R4 and n are as defined in the claims, which are useful pharmaceutically active compounds for the therapy and prophylaxis of illnesses, for example of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis. The compounds of the formula I are capable of modulating the body's production of cyclic guanosine monophosphate “cGMP” and are generally suitable for the therapy and prophylaxis of illnesses which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the formula I, to their use for the therapy and prophylaxis of the abovementioned illnesses and for preparing pharmaceuticals for this purpose, and also to pharmaceutical preparations which comprise the compounds of the formula I.
    Type: Grant
    Filed: September 24, 2002
    Date of Patent: May 24, 2005
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Ursula Schindler, Karl Schönafinger, Hartmut Strobel
  • Patent number: 6881735
    Abstract: The present invention relates to compounds of the formula I wherein A1, A2, R1, R2, R3, X and n are as defined in the claims, which are valuable pharmaceutically active compounds for the therapy and prophylaxis of diseases, for example of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis. The compounds of the formula I are capable of modulating the body's production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of the formula I.
    Type: Grant
    Filed: November 28, 2001
    Date of Patent: April 19, 2005
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Ursula Schindler, Karl Schönafinger, Hartmut Strobel
  • Publication number: 20050026918
    Abstract: The present invention relates to novel pyridazinone derivatives of the general formula (I) wherein A is A1 or A2; R is unsubstituted or at least monosubstituted C1-C10-alkyl, aryl, aryl-(C1-C10-alkyl)-, heteroaryl, heteroaryl-(C1-C10-alkyl)-, heterocyclyl, heterocyclyl-(C1-C10-alkyl)-, C3-C10-cycloalkyl, polycycloalkyl, C2-C10-alkenyl or C2-C10-alkinyl and Ar is unsubstituted or at least monosubstituted aryl or heteroaryl.
    Type: Application
    Filed: November 19, 2003
    Publication date: February 3, 2005
    Inventors: Swen Holder, Thorsten Naumann, Karl Schonafinger, David Will, Hans Matter, Gunther Muller, Dominique Le Suisse, Bernard Baudoin, Thomas Rooney, Franck Halley, Gilles Tiraboschi, Cecile Combeau, Ingrid Sassoon, Anke Steinmetz
  • Publication number: 20040186145
    Abstract: The present invention relates to compounds of the formula I 1
    Type: Application
    Filed: April 2, 2004
    Publication date: September 23, 2004
    Applicant: Aventis Pharma Deutschland GmbH.
    Inventors: Ursula Schindler, Karl Schonafinger, Hartmut Strobel
  • Publication number: 20040176377
    Abstract: The present invention relates to novel pyridazinone derivatives of the general formula (I) 1
    Type: Application
    Filed: November 19, 2003
    Publication date: September 9, 2004
    Inventors: Swen Holder, Thorsten Naumann, Karl Schonafinger, David William Will, Hans Matter, Gunther Muller, Dominique Le Suisse, Bernard Baudoin, Thomas Rooney, Franck Halley, Gilles Tiraboschi
  • Publication number: 20040063690
    Abstract: The present invention relates to compounds of formula I: 1
    Type: Application
    Filed: October 1, 2003
    Publication date: April 1, 2004
    Applicant: AVENTIS PHARMA DEUTSCHLAND GmBH
    Inventors: Ursula Schindler, Karl Schonafinger, Hartmut Strobel